Biotech

07/17/26

Parabilis’ Zolucatetide: The Societal Value of a Drug That Wasn’t Supposed to Exist

Biotech

Science

Finance

06/01/26

RA Capital’s work in China: A personal viewpoint

Biotech

Culture

05/23/26

The paradox of biotech protectionism: Why walling off China biotech weakens America

Biotech

Policy

Finance

05/15/26

It Is Never Too Early – or Too Late – to Tell Your Drug’s Value Story

Biotech

Policy

Finance

05/01/26

The infectious positivity of Mario Barro

Biotech

Science

Culture

04/10/26

I move for joy: Let’s reinvent biotech boards

Biotech

Culture

Finance

03/11/26

The role of insurance in rare disease drug funding

Biotech

Finance

Policy

03/09/26

From IPO to Washington: What planetary health investors can learn from biotech — and vice versa

Biotech

Finance

Planetary

01/21/26

China is the reason why the US’s Most Favored Nation drug pricing experiment will likely be short-lived

Biotech

Finance

Policy

01/10/26

Semper Maior 2026: Biotech M&A – Inside the Room Where It Happens

Biotech

Finance

12/23/25

GLOBE, GUARD, and weighing the ​“most-favored nation” coal in the drug industry’s stocking

Biotech

Finance

Policy

12/19/25

What you were reading — Rapport’s top stories of 2025

Biotech

Culture

Finance

Policy

Science

10/16/25

Three years in: How the IRA’s ​“Fair Pricing” has affected the biopharma development pipeline

Biotech

Policy

09/22/25

The CDC once rescued my faith in science — who will rescue us now?

Biotech

Culture

Policy

Science

09/17/25

Proposals for Modernizing IND Processes, Clinical Trial Development, and Good Clinical Practice Standards

Biotech

Policy

Science

09/15/25

Resolving the Massachusetts Paradox

Biotech

Culture

Policy

09/10/25

Getting personal with three investment leaders at RA Capital

Biotech

Culture

Finance

07/10/25

When getting healthier means your family gets healthier, too

Biotech

Policy

06/26/25

A Cautious FDA Also Threw Out the Baby: In restricting the label for COVID-19 vaccines, the FDA is being too conservative

Biotech

Policy

Science

06/11/25

Your clinical trial enrollment is lagging behind — here’s how to speed it back up

Biotech

Finance